![These highlights do not include all the information needed to use FASLODEX safely and effectively. See full prescribing information for FASLODEX. FASLODEX® (fulvestrant) injection, for intramuscular useInitial U.S. Approval: 2002 These highlights do not include all the information needed to use FASLODEX safely and effectively. See full prescribing information for FASLODEX. FASLODEX® (fulvestrant) injection, for intramuscular useInitial U.S. Approval: 2002](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=NDC0310-0720-10.jpg&id=662856)
These highlights do not include all the information needed to use FASLODEX safely and effectively. See full prescribing information for FASLODEX. FASLODEX® (fulvestrant) injection, for intramuscular useInitial U.S. Approval: 2002
![PDF] Fulvestrant as a reference antiestrogen and estrogen receptor (ER) degrader in preclinical studies: treatment dosage, efficacy, and implications on development of new ER-targeting agents | Semantic Scholar PDF] Fulvestrant as a reference antiestrogen and estrogen receptor (ER) degrader in preclinical studies: treatment dosage, efficacy, and implications on development of new ER-targeting agents | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/6f0ac94f79695924eb81493abfbf833d7b344114/3-Figure1-1.png)
PDF] Fulvestrant as a reference antiestrogen and estrogen receptor (ER) degrader in preclinical studies: treatment dosage, efficacy, and implications on development of new ER-targeting agents | Semantic Scholar
![Pharmacokinetic profile of the fulvestrant loading dose regimen in postmenopausal women with hormone receptor-positive advanced breast cancer. | Semantic Scholar Pharmacokinetic profile of the fulvestrant loading dose regimen in postmenopausal women with hormone receptor-positive advanced breast cancer. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/d64fa7dd85a27501cb846824494db80e816e7919/4-Table2-1.png)
Pharmacokinetic profile of the fulvestrant loading dose regimen in postmenopausal women with hormone receptor-positive advanced breast cancer. | Semantic Scholar
![Ilene Kaminsky on Twitter: "#Fulvestrant #faslodex twice in a month within the first cycle of #Ibrance or oncologist screw up? Anyone hear of Faslodex loading in the first month two weeks apart? # Ilene Kaminsky on Twitter: "#Fulvestrant #faslodex twice in a month within the first cycle of #Ibrance or oncologist screw up? Anyone hear of Faslodex loading in the first month two weeks apart? #](https://pbs.twimg.com/media/D9dOn6PUwAAQxBE.jpg:large)
Ilene Kaminsky on Twitter: "#Fulvestrant #faslodex twice in a month within the first cycle of #Ibrance or oncologist screw up? Anyone hear of Faslodex loading in the first month two weeks apart? #
![Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy | SpringerLink Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs10549-019-05454-y/MediaObjects/10549_2019_5454_Fig4_HTML.png)